LLY
Eli Lilly and Company
LLY has the edge over TRLV overall, supported by stronger fundamentals and lower modeled downside.
TRLV
Trulieve Cannabis Corp.
TRLV trails on the overall score without a compensating advantage in the available component scores.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
TRLV Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Healthy | |
| Strong |
TRLV's cash flow and balance sheet are currently healthy, but its revenue and profitability are under pressure.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
TRLV PE Valuation
TRLV has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over TRLV on the outlook, with more favorable revenue expectations.
TRLV Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Decline | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect TRLV's earnings to grow and its profitability to improve, but its revenue to decline. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over TRLV on earnings quality, reporting a profit while its opponent remains loss making.
TRLV Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.37 | — |
| Q3 2026 | -$2.30 | -$1.66 |
| Q2 2026 | -$2.44 | -$1.62 |
| Q1 2026 | -$0.41 | +$0.38 |
| Q4 2025 | -$0.58 | +$0.21 |
| Q3 2023 | -$2.62 | -$1.35 |
| Q2 2023 | -$2.91 | -$2.19 |
| Q1 2023 | -$1.23 | -$0.94 |
| Q4 2022 | -$1.06 | -983% |
TRLV is still losing money, but less than at its worst: $2.30 per share over the past year, against $2.91 at its worst in mid-2023.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over TRLV on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over TRLV on profitability, with a higher operating margin.
TRLV Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $230.2M | -20% |
| Q2 2026 | $271M | -10% |
| Q1 2026 | $286.8M | -3.7% |
| Q4 2025 | $293.1M | -2.7% |
| Q3 2025 | $288.2M | +1.4% |
| Q2 2025 | $302.1M | -0.4% |
| Q1 2025 | $297.8M | 0% |
| Q4 2024 | $301.1M | +4.9% |
TRLV's revenue has slid since its 2022 peak: $230M last quarter, down 20% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 18% | +3.8 points |
| Q2 2026 | -137% | -154 points |
| Q1 2026 | 12% | +1.3 points |
| Q4 2025 | 5.2% | +4.8 points |
| Q3 2025 | 15% | +14 points |
| Q2 2025 | 17% | +1 points |
| Q1 2025 | 11% | -4.3 points |
| Q4 2024 | 0.4% | -9.7 points |
TRLV's operating margin was 18% last quarter, up 3.8 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over TRLV on cash flow, with more consistent year-over-year improvement.
TRLV Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $45.4M | -30% |
| Q2 2026 | $32.1M | -57% |
| Q1 2026 | $42.2M | +25% |
| Q4 2025 | $55.8M | +$67.6M |
| Q3 2025 | $64.4M | +$71M |
| Q2 2025 | $74.5M | +66% |
| Q1 2025 | $33.9M | -73% |
| Q4 2024 | -$11.8M | -110% |
TRLV still generates free cash flow, though less than at its 2024 peak: $176M over the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over TRLV on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
TRLV Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.1% | +7.9M shares |
| 1 year | +4.9% | +9.3M shares |
| 3 years | +6.2% | +11.7M shares |
| 5 years | +47% | +63.7M shares |
TRLV has 201M diluted shares, up 4.9% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
TRLV Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -0.6x | Net Cash |
| Q4 2025 | -0.5x | Net Cash |
| Q3 2025 | -0.3x | Net Cash |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | 0.2x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | 0.5x | Very low |
| Q2 2024 | 0.0x | Very low |
TRLV has more cash than debt.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
TRLV Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.1 | Neutral |
| Stochastic | 59.2 | Neutral |
TRLV's weekly RSI is 56 (neutral) and its Stochastic is 59 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
TRLV PE vs Healthcare Sector
TRLV has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
TRLV Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.9 | 2.5% above |
| 20 week MA | $10.4 | 7.7% above |
| 50 week MA | $8.85 | 26% above |
| 100 week MA | $7.06 | 58% above |
| 200 week MA | $7.29 | 53% above |
TRLV has climbed back above all five of its weekly moving averages, and it's now 53% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.
TRLV Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $10.8 | $31.9 | +195% |
| 2021 | $31.9 | $26.8 | -16% |
| 2022 | $26.8 | $7.58 | -72% |
| 2023 | $7.58 | $5.21 | -31% |
| 2024 | $5.21 | $4.78 | -8.3% |
| 2025 | $4.78 | $7.89 | +65% |
| 2026 YTD | $7.89 | $11.2 | +41% |
TRLV has the edge over LLY on returns for 2026, with the stronger performance.